Vitaspring Biomedical Co Stock Net Income
| VSBC Stock | USD 0.01 0.99 98.89% |
As of the 15th of February 2026, VitaSpring Biomedical has the Variance of 148.17, risk adjusted performance of (0.09), and Coefficient Of Variation of (812.40). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of VitaSpring Biomedical, as well as the relationship between them.
VitaSpring Biomedical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing VitaSpring Biomedical's valuation are provided below:VitaSpring Biomedical Co does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. VitaSpring |
VitaSpring Biomedical 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to VitaSpring Biomedical's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of VitaSpring Biomedical.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in VitaSpring Biomedical on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding VitaSpring Biomedical Co or generate 0.0% return on investment in VitaSpring Biomedical over 90 days. VitaSpring Biomedical is related to or competes with Paradigm Biopharmaceutica, Satellos Bioscience, Kintor Pharmaceutical, Nuo Therapeutics, Imugene, Starpharma Holdings, and Shield Therapeutics. The company was formerly known as Shemn Corp More
VitaSpring Biomedical Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure VitaSpring Biomedical's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess VitaSpring Biomedical Co upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 98.89 |
VitaSpring Biomedical Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for VitaSpring Biomedical's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as VitaSpring Biomedical's standard deviation. In reality, there are many statistical measures that can use VitaSpring Biomedical historical prices to predict the future VitaSpring Biomedical's volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (1.71) | |||
| Total Risk Alpha | (2.41) | |||
| Treynor Ratio | (0.46) |
VitaSpring Biomedical February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.45) | |||
| Mean Deviation | 2.95 | |||
| Coefficient Of Variation | (812.40) | |||
| Standard Deviation | 12.17 | |||
| Variance | 148.17 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (1.71) | |||
| Total Risk Alpha | (2.41) | |||
| Treynor Ratio | (0.46) | |||
| Maximum Drawdown | 98.89 | |||
| Skewness | (8.12) | |||
| Kurtosis | 66.0 |
VitaSpring Biomedical Backtested Returns
VitaSpring Biomedical owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.12, which indicates the firm had a -0.12 % return per unit of risk over the last 3 months. VitaSpring Biomedical Co exposes eighteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate VitaSpring Biomedical's Coefficient Of Variation of (812.40), variance of 148.17, and Risk Adjusted Performance of (0.09) to confirm the risk estimate we provide. The entity has a beta of 3.28, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, VitaSpring Biomedical will likely underperform. At this point, VitaSpring Biomedical has a negative expected return of -1.55%. Please make sure to validate VitaSpring Biomedical's standard deviation and the relationship between the jensen alpha and day typical price , to decide if VitaSpring Biomedical performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.00 |
No correlation between past and present
VitaSpring Biomedical Co has no correlation between past and present. Overlapping area represents the amount of predictability between VitaSpring Biomedical time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of VitaSpring Biomedical price movement. The serial correlation of 0.0 indicates that just 0.0% of current VitaSpring Biomedical price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 0.49 | |
| Residual Average | 0.0 | |
| Price Variance | 0.08 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, VitaSpring Biomedical Co reported net income of 1.26 M. This is 99.63% lower than that of the Healthcare sector and 98.2% lower than that of the Biotechnology industry. The net income for all United States stocks is 99.78% higher than that of the company.
VitaSpring Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses VitaSpring Biomedical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of VitaSpring Biomedical could also be used in its relative valuation, which is a method of valuing VitaSpring Biomedical by comparing valuation metrics of similar companies.VitaSpring Biomedical is currently under evaluation in net income category among its peers.
VitaSpring Fundamentals
| Return On Equity | 0.84 | |||
| Return On Asset | 0.41 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.24 % | |||
| Current Valuation | 2.89 B | |||
| Shares Outstanding | 206.52 M | |||
| Shares Owned By Insiders | 58.70 % | |||
| Price To Book | 1,622 X | |||
| Price To Sales | 558.27 X | |||
| Revenue | 5.61 M | |||
| Gross Profit | 2.06 M | |||
| EBITDA | 1.49 M | |||
| Net Income | 1.26 M | |||
| Cash And Equivalents | 21.59 K | |||
| Total Debt | 375.5 K | |||
| Debt To Equity | 0.21 % | |||
| Current Ratio | 4.23 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | 84.81 K | |||
| Beta | 1.43 | |||
| Market Capitalization | 3.1 B | |||
| Total Asset | 3.6 M | |||
| Net Asset | 3.6 M |
About VitaSpring Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze VitaSpring Biomedical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of VitaSpring Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of VitaSpring Biomedical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in VitaSpring Pink Sheet
VitaSpring Biomedical financial ratios help investors to determine whether VitaSpring Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in VitaSpring with respect to the benefits of owning VitaSpring Biomedical security.